Full-Time
Patient Education Manager
Rhythm Pharmaceuticals
201-500 employees
Commercializes MC4R-targeted therapies for rare obesity
Compensation Overview
$135k - $215k/yr
Seattle, WA, USA
In Person
Territory primarily covers Seattle, Washington, Oregon, and surrounding areas; up to 50% travel is required.
Bachelor's
 Medical, Clinical & Veterinary (1) |
|---|
Get referred to Rhythm Pharmaceuticals
See people who can refer or advise you
- A bachelor's degree is required, with a background in nursing, social work, dietetics, or clinical practice.
- At least 6 years of related experience, including experience supporting patients within rare disease.
- Knowledge of the insurance and payer landscape and the United States reimbursement process.
- Ability to work quickly and flexibly with resource constraints while maintaining a results-driven approach.
- Ability to work independently and collaboratively with a diverse team.
- Ability to travel in the United States, up to 50% of the time.
- Willingness and ability to travel frequently and have easy access to transportation and airports.
- Compliance with corporate and industry policies and legal and regulatory requirements for regional commercial activities.
- Deliver in-depth disease-state and product education to inform and empower patients and caregivers as they navigate treatment access.
- Identify and resolve patient-specific barriers and develop action plans so patients and caregivers can manage their disease and treatment as recommended by their healthcare provider.
- Deliver education programs, both in person and virtually, including injection education training for patients and families.
- Provide care coordination for patients and caregivers by liaising with the Field Access Manager, Territory Manager, sales team, and specialty pharmacy to facilitate reimbursement and fulfillment.
- Collaborate with cross-functional partners on complex patient and customer issues.
- Respond to customer inquiries, provide appropriate education and support, and triage customers to available resources.
- Maintain a comprehensive understanding of regional payer and customer trends.
- Meet documentation requirements to facilitate tracking of critical metrics.
- Prior product launch experience.
Rhythm Pharmaceuticals develops and commercializes therapies for rare neuroendocrine and genetic obesity disorders. Its lead drug, IMCIVREE (setmelanotide), is an MC4R agonist that helps restore signaling in the melanocortin-4 pathway to regulate hunger and energy use. The company earns revenue primarily from global IMCIVREE sales and reinvests in research, development, and commercialization. Its aim is to broaden MC4R-targeted treatments for underserved patients and advance additional candidates like bivamelagon and RM-718 through clinical development.
Company Size
201-500
Company Stage
IPO
Headquarters
Boston, Massachusetts
Founded
2008
Get referred to Rhythm Pharmaceuticals
See people who can refer or advise you
Simplify's Take
What believers are saying
- Q2 2026 IMCIVREE revenue reached $71.3 million, up 19% sequentially.
- August 2026 RM-718 delivered 11.6% BMI reduction at week 16 in HO patients.
- August 2026 Manher Joshi joined as CMO, strengthening late-stage development execution.
What critics are saying
- March 2026 EMANATE missed four primary endpoints, weakening expansion beyond current labels.
- IMCIVREE depends on rare-disease diagnosis, payer access, and narrow prescriber adoption.
- Setmelanotide-class adverse events, including nausea and injection reactions, threaten chronic-use persistence.
What makes Rhythm Pharmaceuticals unique
- March 2026 FDA approved IMCIVREE first for acquired hypothalamic obesity.
- Rhythm owns MC4R biology, spanning setmelanotide, bivamelagon, and RM-718 programs.
- BBS and genetic-obesity diagnostics create a rare, specialist-driven commercial moat.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Hybrid Work Options
Performance Bonus
Company Equity
Growth & Insights and Company News
6 month growth
↑ 5%1 year growth
↑ 8%2 year growth
↑ 3%Rhythm Pharmaceuticals has appointed Manher "AJ" Joshi as Chief Medical Officer, effective 17 August. Dr Joshi brings over 20 years of experience spanning drug discovery, pivotal trials, regulatory processes and lifecycle management. Dr Joshi joins from Soleno Therapeutics, where he served as Chief Development Officer. He previously held the Chief Medical Officer position at Neurona Therapeutics and executive roles at Atara Biotherapeutics. His career also includes leadership positions at Allergan Medical, Synageva BioPharma, and Genzyme. Rhythm is a commercial-stage biopharmaceutical company focused on rare neuroendocrine diseases. Its lead asset, IMCIVREE (setmelanotide), is approved in the US and Europe for treating certain forms of obesity. The company is advancing next-generation MC4R agonists through late-stage development.
Rhythm Pharmaceuticals announced that the UK's Medicines and Healthcare products Regulatory Agency has expanded the marketing authorisation for IMCIVREE (setmelanotide) to include treatment of obesity and control of hunger in adults and children aged 4 and older with acquired hypothalamic obesity due to hypothalamic injury or impairment. The MHRA also granted IMCIVREE orphan drug designation for acquired HO. The approval is based on results from the Phase 3 TRANSCEND trial, which met its primary endpoint with a statistically significant 19.8% placebo-adjusted reduction in body mass index. The global trial enrolled 120 patients. IMCIVREE initially received marketing authorisation in the UK in 2021 for treatment of obesity in patients with POMC, PCSK1 or LEPR deficiency, with subsequent expansions for other rare obesity conditions.
Rhythm Pharmaceuticals reported preliminary results showing its experimental weekly injectable drug RM-718 helped reduce body weight in patients with acquired hypothalamic obesity, a rare condition caused by brain damage from tumour surgery or treatment. The Boston-based company's shares rose 5% in premarket trading. Among 11 enrolled patients, seven who completed 16 weeks of treatment saw their body mass index fall by an average of 11.6%. The drug works by activating the MC4R brain receptor, which controls hunger and metabolism. Two patients discontinued treatment due to side effects including nausea and injection site problems. Rhythm also sells setmelanotide for the same condition under the brand name Imcivree. Separately, the company reported second-quarter revenue of $71.3 million, up 46.9% from $48.5 million a year earlier.
Rhythm Pharmaceuticals reported second quarter 2026 net product revenue of $71.3 million from global sales of IMCIVREE, marking a 19% sequential increase from the first quarter. The company received over 400 patient start forms for IMCIVREE's acquired hypothalamic obesity indication from approximately 300 prescribers as of 30 June 2026, following FDA approval in March. US revenue reached $51.0 million, representing 72% of product revenue and a 38% sequential increase, driven primarily by acquired hypothalamic obesity demand. The company reported preliminary Phase 2 data showing weekly injectable MC4R agonist RM-718 achieved mean BMI reduction of 11.6% in acquired hypothalamic obesity patients after 16 weeks. Cash, cash equivalents, and short-term investments totalled approximately $330.9 million as of 30 June 2026. The company posted a net loss of $50.4 million for the quarter.
Rhythm Pharmaceuticals has published an updated diagnostic algorithm for Bardet-Biedl syndrome in the American Journal of Medical Genetics, designed to help clinicians achieve faster diagnoses using modern genetic testing. The evidence-based framework simplifies recognition of the complex, multi-organ rare disease across age groups and specialties. The new algorithm could expand identification of eligible patients for Rhythm's IMCIVREE treatment and strengthen relationships with the Bardet-Biedl syndrome community and physicians. This follows Rhythm's recent expanded indication for IMCIVREE in acquired hypothalamic obesity in the US and Europe. Whilst the algorithm may broaden patient identification, investors remain focused on Rhythm's commercial execution, persistent operating losses and reliance on setmelanotide. The company's investment case depends on converting rare genetic obesity awareness into sustainable treatment demand.